Latest In: Epidiolex

Australia Epidiolex Epidyolex GW Pharmaceuticals

GW Pharmaceuticals cannabis drug gets regulatory OK in Australia

GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in…

News September 24
Epidiolex GW Pharmaceuticals United Kingdom

Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact

United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges…

News August 7
cannabidiol cbd Dravet syndrome Epidiolex FDA GW Pharmaceuticals Lennox-Gastaut syndrome tuberous sclerosis complex U.S. Food and Drug Administration

FDA approves GW Pharmaceuticals’ cannabis drug for new indication

CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a…

News August 3
cannabidiol Epidiolex Epidyolex GW Pharmaceuticals United Kingdom

UK down-schedules Epidyolex to lowest level for controlled drugs

The United Kingdom has down-scheduled Epidyolex to the lowest level of control for drugs, greatly easing restrictions on…

News June 24
coronavirus Epidiolex week in review

Week in Review: Cannabis firm iAnthus can’t make interest payments, MA gov sued, COVID-19 causes slide in adult-use marijuana sales & more

Multistate marijuana operator iAnthus defaulted on interest payments, in part blaming the coronavirus. In addition, the New York-based…

News April 11
dea Epidiolex FDA GW Pharmaceuticals

DEA removes cannabis drug Epidiolex from controlled substances list

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered…

News April 7
Australia cannabidiol Epidiolex GW Pharma Sativex

Australia expedites review of medical cannabis product Epidiolex

The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another.

News January 30
Epidiolex GW Pharmaceuticals Sativex

GW Pharma beats projections with $108M in Q4 sales thanks to CBD drug

A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana.

News January 13
Epidiolex nabilone Sativex

New UK guidelines recommend public insurance coverage for two GW Pharma cannabis medicines, plus a synthetic cannabinoid

New British guidelines for the first time recommend that two plant-based cannabis medicines – Sativex and Epidiolex –…

News November 12
MJBizCon Logo